Shares of Danish biotech company Bavarian Nordic jumped in early deals on Thursday after it reported stronger-than-expected earnings.
The order was planned as part of Bavarian Nordic's original 2024 guidance and, as such, will not impact remaining capacity this year, the company said.mpox a global public health emergency following the spread of an outbreak in the Democratic Republic of Congo to neighboring countries.CEO Paul Chaplin said the order showed a growing acknowledgement from some countries of the need for greater preparedness following an earlier outbreak in 2022.
He added that the company still has capacity to supply up to 10 million doses of the vaccine by the end of next year, two million of which will be available over the course of this year.